Overexpression of the high mobility group I (HMGI) proteins is often associated with the malignant phenotype. Moreover, many benign human tumors, mainly of mesenchymal origin, are characterized by rearrangements of the HMGI-C gene. In most cases, HMGI-C alterations involve breaks within the third intron of the gene resulting in aberrant transcripts carrying exons from 1 ± 3, which encode the three DNA binding domains, fused to ectopic sequences. Here, we show that the expression of a truncated form of HMGI-C protein carrying only the three DNA-binding domains, or of a fusion protein carrying the three DNA-binding domains of HMGI-C and the LIM domains of the lipoma preferred partner gene (LPP) protein, causes malignant transformation of NIH3T3 cells. The unrearranged wildtype HMGI-C cDNA did not exert any transforming activity. These ®ndings indicate that rearranged forms of HMGI-C play a role in cell transformation.
Introduction
The HMGI-C protein belongs to the high mobility group (HMG) of DNA-binding proteins, which are abundant, heterogeneous, nonhistone components of chromatin (Grosschedl et al., 1994) . High mobility group proteins are divided into three distinct families. The best understood functionally is the HMGI family that consists of three members: HMGI and HMGY, which are products of alternative splicings of the same gene, named HMGI(Y) (Friedmann et al., 1993; Eckner and Birnstiel, 1989; Johnson et al., 1989) and HMGI-C, which is coded for by a separate gene (Man®oletti et al., 1991; Patel et al., 1994; Chan et al., 1995) . All HMGI proteins contain about 100 amino acids, three basic DNA-binding domains in the Nterminal part of the protein and a highly acidic Cterminal domain of 15 amino acids (Ferranti et al., 1992) . They have no transcriptional activity per se (Wole, 1994) , but HMGI(Y) proteins participate in the assembly of protein complexes on the promoters of several inducible genes and can, thus, be de®ned architectural factors' (Thanos and Maniatis, 1992; Lewis et al., 1994; Chuvpilo et al., 1993; Du et al., 1993) .
We previously demonstrated an association between the increased expression of HMGI proteins and cell transformation (Giancotti et al., 1985 (Giancotti et al., , 1987 (Giancotti et al., , 1989 . HMGI proteins are highly expressed during embryogenesis, but not at signi®cant levels in dierentiated adult tissues Zhou et al., 1995) . However, their expression is consistently induced in transformed epithelial cells of thyroid and colonic origin (Chiappetta et al., 1995; Fedele et al., 1996) .
We have demonstrated a more direct involvement of HMGI-C in transformation . In fact, cells infected by oncogenic retroviruses failed to exhibit phenotypic markers of neoplastic transformation if HMGI-C protein synthesis was speci®cally inhibited by anti-sense constructs.
Rearrangements of the HMGI-C gene have been recently identi®ed in a variety of benign human tumors mainly of mesenchymal origin: uterine leiomyomas (Schoenmakers et al., 1995) , lipomas (Schoenmakers et al., 1995; Ashar et al., 1995) , pulmonary chondroid hamartomas (Schoenmakers et al., 1995; Kazmierczak et al., 1996) , endometrial polyps (Bol et al., 1996) ; pleomorphic adenomas of the salivary glands (Schoenmakers et al., 1995) , and ®broadenomas of the breast (Staats et al., 1996) . The HMGI-C rearrangements caused by breaks within the third intron of the gene. They result in chimeric transcripts containing exons from 1 ± 3 of HMGI-C and ectopic sequences from other genes. In lipomas the preferred fusion partner gene of HMGI-C is the`lipoma preferred partner' (LPP) gene. This gene encodes a proline-rich protein containing a leucine-zipper motif in its amino-terminal region and three LIM domains in its carboxy-terminal region (Freyd et al., 1990) . These three LIM domains are fused to HMGI-C (Petit et al., 1996) . However, in some of these mesenchymal tumors, only a few amino acids are fused to the HMGI-C DNA binding domains suggesting that the truncation of the HMGI-C gene, rather than its fusion with other genes, is responsible for cell transformation.
We have investigated whether the expression of a truncated form of HMGI-C protein, carrying only the three DNA-binding domains, or a chimeric protein, in which the three DNA-binding domains are fused to the LIM domains of LPP, is able to induce cell transformation. We have transfected the NIH3T3 murine ®broblasts with the empty vector, the HMGI-C gene, a truncated form of HMGI-C (HMGI-C/T, where T means`truncated') or a chimeric HMGI-C/ LPP gene (HMGI-C/C, where C means`chimeric'). Both the truncated HMGI-C and the chimeric HMGI-C/LPP, but not the wild-type gene or the empty vector, induced neoplastic transformation of NIH3T3 cells.
Results

The transforming activity of rearranged HMGI-C constructs
To examine the transforming potential of the HMGI-C gene and of its truncated and chimeric forms (HMGI-C/T and HMGI-C/C, respectively), we ®rst constructed plasmids that express these mRNAs in eukaryotic cells. cDNA encoding either the wild-type HMGI-C or the truncated form (HMGI-C/T) was inserted into the HindIII or HindIII ± XbaI sites, respectively, of the expression vector pRc/CMV (Invitrogen). The HMGI-C truncated construct (pHMGI-C/T) carries the three DNA binding domains of the protein and lacks the acidic and spacer domains (Figure 1 ). The chimeric construct (pHMGI-C/C), carrying a cDNA coding for the three DNA binding domains of HMGI-C fused to the three LIM domains of LPP (Petit et al., 1996) was inserted into the EcoRI site of the expression vector pCR3.1 (Invitrogen) (Figure 1 ). As controls, we used the empty vector and a construct carrying a Ret mutant (Cys 634 to Tyr) associated with the MEN2A syndrome, which has a powerful transforming capacity in NIH3T3 cells .
These plasmids were transfected into NIH3T3 cells to test their transforming activity. Both HMGI-C/T and HMGI-C/C induced transformation foci (Figure 2 ) with a lower focus-forming ability (1610 2 f.f.u./pmol) compared to the positive control Ret-MEN2A (3610 3 ) (Table 1) . Moreover, HMGI-C/T and HMGI-C/C transformation foci appeared at about 30 days after transfection whereas they appeared at about 10 days post-transfection in the Ret-MEN2A positive control. Conversely, wild-type HMGI-C failed to induce transformation, and no foci were dectected in the mock-transfected NIH3T3 cells. These results demonstrate that HMGI-C/T and HMGI-C/C have transforming ability, but less than that shown by a wellknown oncogene such as Ret-MEN2A.
The transformed phenotype of stable transfectants
Cell populations resistant to G418 were selected, grown and analysed for the expression of the transfected cDNAs. Four representative clones transfected with pHMGI-C/T, three with pHMGI-C/C, and a mass population transfected with wild-type pHMGI-C were examined. Reverse-transcriptase-polymerase chain reaction (RT ± PCR) analyses showed that the transfected HMGI-C/T, HMGI-C/C and HMGI-C cDNAs were expressed in these G418-resistant NIH3T3 cells, but not in mock-transfected ones ( Figure 3) . A semiquantitative (20 ampli®cation cycles) RT ± PCR experiment con®rmed that both pHMGI-C/C and pHMGI-C/T constructs were expressed at similar levels (data not shown).
To characterize the phenotype of these stable transfectants, we analysed their ability to grow in soft agar and to induce tumors in athymic mice. pHMGI-C/T and pHMGI-C/C-transfected NIH3T3 cells formed large, progressively growing colonies in soft agar ( Figure 2 ) with an eciency of 30%. In contrast, NIH3T3 cell transfectants expressing wild-type HMGI- Figure 1 Schematic representation of plasmids used in this study: pHMGI-C, pHMGI-C/T and pHMGI-C/C carrying the cDNA for the wild-type, truncated and chimeric HMGI-C gene, respectively C or the empty vector did not form colonies in soft agar (Table 1) . Ret-MEN2A transfected cells showed a colony-forming eciency of 80%.
Subcutaneous injection of pHMGI-C/T and pHMGI-C/C transfected cells into athymic mice give rise to tumors within about 10 days, while no tumors were observed in mock-and pHMGI-C transfected NIH3T3 cells (Table 1) .
Growth properties of NIH3T3 transfectants
We investigated whether the adoptive expression of HMGI-C/T, HMGI-C/C or HMGI-C genes aected the growth pro®le of the NIH3T3 cells. Figure 4a shows the growth curves, in 5% calf serum, of a mass population of wild-type HMGI-C transfected cells and two representative HMGI-C/T or HMGI-C/C transfected clones compared to the growth of mocktransfected cells. The saturation cell density of the two mutated HMGI-C transfectants was signi®cantly higher than that of wild-type HMGI-C and mock transfected cells. When the same cell lines were cultured in 1% serum, a signi®cant dierence between mutated HMGI-C transfectants and mock-transfected cells also appeared in the doubling time (30 h for HMGI-C/T and HMGI-C/C transfectants versus 37 h for mock-transfected cells) (Figure 4b ), underscoring a reduction of the serum dependency exerted by the HMGI-C/C and HMGI-C/T cells. Conversely, proliferation rate and saturation cell density did not dier between mock-and wild-type HMGI-C transfected cells (Figure 4) . These results are summarized in Table 2 .
Discussion
We have previously demonstrated that the HMGI-C protein is highly expressed in transformed thyroid cells (Giancotti et al., 1987) . The inhibition of HMGI-C synthesis impaired transformation of rat thyroid cells by v-mos and v-ras-ki oncogenes indicating that HMGI-C overexpression plays an important role in neoplastic transformation.
The analysis of several benign mesenchymal tumors carrying a translocation aecting band q15 of Figure 2 Photograph of the transformed phenotypes of primary transfectants with pHMGI-C/T and pHMGI-C/C expression vectors. The primary transfectants with pHMGI-C, pHMGI-C/T or pHMGI-C/C expression vectors were used for colony formation assay (AGAR) or focus formaton assay (DISH) as described in Materials and methods. The photographs (100-fold magni®cation) were taken on day 30 (dish) and on day 14 (agar) . Lanes 1 ± 8: primers FP1 and DP1 were used. Lanes 9 ± 14: primers FP2 and DP2 were used chromosome 12, where the HMGI-C gene maps, showed rearrangements of the HMGI-C gene. In most of the cases the breakpoint occurred in the long third intron between the DNA-binding and the spacer/acidic domains, and caused the HMGI-C DNA-binding domains to fuse with ectopic sequences from other genes (e.g. the LIM domains of the LPP gene) or to short sequences, without any evident function (Schoenmakers et al., 1995; Ashar et al., 1995) . It remains to be established whether rearranged HMGI-C genes act as dominant oncogenes. In this work we have investigated whether the most frequent rearranged form of HMGI-C in lipomas, HMGI-C/ LPP, is able to transform cells in culture. We have also analysed the transforming ability of a truncated form of HMGI-C in order to investigate whether the loss of the spacer and acidic domains is sucient to confer oncogenic properties to the HMGI-C gene, or alternatively, whether the acquisition of ectopic sequences represents a necessary event to confer transforming ability to this gene. Our results show that the rearranged form HMGI-C/LPP has transforming activity on NIH3T3 ®broblasts. In fact, transforming foci appeared in these cells 3 ± 4 weeks after transfection. The G418-selected transfectants expressed the typical markers of neoplastic transformation, i.e. they were able to grow in soft agar and to induce tumors when inoculated into athymic mice. Analogous results, both in the number of foci and the degree of malignancy, were obtained with transfection of the truncated HMGI-C gene.
Taken together, these data strongly suggest that HMGI-C rearrangements play an important role in the development of neoplasias. They also demonstrate that the loss of the two last exons of HMGI-C is sucient to confer transformation ability. Moreover, the acquisition of ectopic sequences does not increase the transforming ability of the HMGI-C truncated form. Obviously, it cannot be excluded that for the transformation of cell lines other than NIH3T3 ®broblasts, the ectopic sequences might be required and/or could increase its transforming ability.
Interestingly, the transforming ability of the rearranged forms of the HMGI-C gene is quite weak. In fact, the number of foci was signi®cantly lower (about 30-fold) than that obtained transfecting Ret/MEN2A or activated ras genes (data not shown). Moreover, these foci appeared with a longer latency period (3 ± 4 weeks versus 1 ± 2 weeks for the appearance of Ret/ MEN2A foci). Finally, the colony-forming eciency in soft-agar of the HMGI-C/T and HMGI/LPP transfectants was lower (30 ± 35%) compared to that of Ret/ MEN2A transfectants (80%). Although the results obtained from the in vitro NIH3T3 cell system cannot be completely transferred to in vivo tumors, these data are consistent with the benign and non-aggressive behavior of tumors associated with rearranged HMGI-C forms. No foci were obtained when a wildtype HMGI-C gene was transfected on NIH3T3 ®broblasts. These results con®rm those obtained with rat thyroid cells . Moreover, the growth properties of the wild-type HMGI-C transfected NIH3T3 cells resulted indistinguishable from those of parental-mock-transfected cells. However, since untransfected NIH3T3 cells express signi®cant levels of endogenous HMGI-C (Fedele M, unpublished results), they do not represent the best model to analyse the eects of a high level expression of wildtype HMGI-C. We are trying to analyse this aspect by constructing transgenic mice overexpressing mutated and wild-type HMGI-C constructs. These transgenic Figure 4 Growth characteristics of the stable transfectants in 5% (a) and in 1% (b) calf serum. The mock, wild-type HMGI-C, HMGI-C/T and HMGI-C/C transfected NIH3T3 cells were grown in DMEM medium supplemented with 5% (a) or 1% (b) calf serum and counted daily. The data reported are the average results of two independent experiments. Error bars are also shown CS=calf serum. HMGI-C, HMGI-C/T and HMGI-C/C are the plasmids carrying the wild-type, the truncated and the chimeric HMGI-C cDNA, respectively
Oncogenic properties of the HMGI-C gene M Fedele et al mice will also allow us to better de®ne the histologic features of tumors caused in vivo by the rearranged HMGI-C forms.
At the present time, we can only speculate about the mechanisms by which rearranged forms of HMGI-C are able to induce cell transformation. HMGI proteins are involved in transcriptional regulation (either positive or negative) of a number of mammalian genes, e.g. TNF-b, b-interferon, E-selectin and interleukin-4 genes, lying in close proximity to AT-rich promoter/enhancer sequences (Fashena et al., 1992; Thanos and Maniatis, 1992; Whitley et al., 1994; Lewis et al., 1994; Chuvpilo et al., 1993) . HMGI proteins function as`architectural transcription factors' both by bending DNA and by directly interacting with other transcription factors, such as NF-kB, ATF-2, IRF and c-Jun (Du and Maniatis, 1994) . Moreover, we have recently demonstrated that HMGI-C plays an important role in the induction of AP-1 activity in thyroid cells by regulating transcription of Fra1 and JunB genes (Vallone et al., 1997) . Thus, it is conceivable that the rearranged forms of HMGI-C can interfere in a dominant fashion with the activity of some HMGI-Cdependent transcription factors, an event that would account for their transforming ability.
Materials and methods
Cell culture conditions and transfection experiments
NIH3T3 cells were grown in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% fetal calf serum and were transfected using the calcium phosphate precipitation method as described elsewhere . Transforming eciency was calculated in FFUs per pmol of added DNA after normalization for the eciency of colony formation in parallel dishes subjected to marker selection with G418. Marker-selected mass populations of transfected NIH3T3 cells were obtained by growing the transfectants in the presence of G418 (400 mg ml 71 ).
Plasmids cDNAs encoding the wild-type or a truncated form of murine HMGI-C were subcloned into the HindIII or HindIII ± XbaI sites, respectively, of the expression vector pRc/CMV (Invitrogen) (Figure 1 ). The truncated HMGI-C lacks the two last exons corresponding to the spacer and acidic domains. cDNA encoding the chimeric HMGI-C/C gene, composed of the three HMGI-C DNA binding domains fused to the three LPP LIM domains, was subcloned into the EcoRI site of the expression vector pCR3.1 (Invitrogen) (Figure 1 ). The pRc/CMV and pCR3.1 vectors contain a pCMV promoter and downstream of the cDNA cloning site the polyadenylation and transcription termination sequences from the bovine growth hormone (BGH) gene to enhance RNA stability and the SV40 origin for episomal replication. cDNA encoding the mutated Ret (Cys634 to Tyr), associated to MEN2A, was inserted into the expression vector pLTR-2 (Di as described and in the HindIII site of the pRc/CMV vector (Invitrogen).
Cell proliferation assay
The cells (10 5 /dish) were plated in 60 mm plates and cultured in the presence of 5% or 1% calf serum. Cells were counted every day for 10 consecutive days to extrapolate the growth curves. The doubling time was measured when the cells were in the logarithmic phase of growth, and the saturation density was determined when the cell numbers reached a plateau. The experiments were performed in duplicate.
In vitro and in vivo analysis of transformed phenotype Soft agar assays were performed according to the technique described (Macpherson and Montagnier, 1964) . Brie¯y, NIH3T3 transfectants were suspended in 0.5% Noble agar in Ham's F12 supplemented with 10% calf serum at a density of 2610 4 or 4610 4 per 1.5 ml. This solution was overlayed on 7 ml 0.5% Noble agar in 10% calf serumHam's F12 in 60-mm dishes. The cells were incubated in 5% CO 2 at 378C. Colonies larger than 64 cells were counted 14 days after plating and the results were expressed as the ratio [(number of colonies formed/ number of plated cells)6100]. Tumorigenicity was evaluated by inoculating mock-and HMGI-C/T transfected cells (5610 5 cells/mouse) subcutaneously into four athymic nude mice. Tumor occurrence was evaluated 14 days after inoculation and monitored at least once a week for 4 weeks.
RNA extraction and RT ± PCR
Total RNA was extracted using the guanidine thiocyanate method (Chomczyniski and Sacchi, 1987) . cDNA was synthesized using random hexamers and AMV reverse transcriptase (Boehringer). Primers for the PCR were designed to speci®cally amplify the transcripts of the transfected constructs. For both pHMGI-C and pHMGI-C/T constructs the forward primer FP1 (5'-ATA-TAAGCTTGGTACCGGTAGAGGCAGTGG-3') overlapping the 5' of the cloned genes, and the downstream primer DP1 (5'-AGTCGAGGCTGATCAGCGAG-3') overlapping the vector pRc/CMV, downstream of the cloned gene but upstream of the poly A signal site, were used. Conversely, for the pHMGI-C/C construct the forward primer FP2 (5'-GTCTTCCACGTGGATTGTTT-3'), overlapping the LPP part of the cloned chimeric gene, and the downstream primer DP2 (5'-AACTAGAAGGCACAGTCGAG-3') overlapping the vector pCR3.1 downstream of the cloned gene but upstream of the poly A signal site, were used. PCR was performed in a 25 ml volume containing 10 mmol/l tris/HCl pH 8.0, 50 mmol/l KCl, 2 mmol/l MgCl 2 , 200 mmol/l dATP, 200 mmol/l dTTP, 200 mmol/l dGTP, 200 mmol/l dCTP, 200 nmol/l upper primer, 200 nmol/l lower primer and 2.5 U/100 ml Amplitaq polymerase (Polymed). Ampli®cation was performed for 30 cycles (30 s at 948C, 30 s at 558C, 30 s at 728C) using the Gene Amp PCR System 2400 (Perkin Elmer). As a negative control, a PCR ampli®cation of RNA samples which were not reverse transcribed before PCR amplification, was performed (data not shown).
The PCR products were separated on 2% agarose gel, blotted and hybridized with a 290 bp HMGI-C cDNA probe labeled with [a 32 P]dCTP using an oligolabeling method (Ready-to-go, Pharmacia) to 7610 8 c.p.m./mg speci®c activity. Hybridization and detection were performed as previously described (Sambrook et al., 1989) .
